KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Net Income towards Common Stockholders (2016 - 2025)

Emergent BioSolutions (EBS) has 14 years of Net Income towards Common Stockholders data on record, last reported at -$54.6 million in Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders fell 74.44% year-over-year to -$54.6 million; the TTM value through Dec 2025 reached $52.6 million, up 127.6%, while the annual FY2025 figure was $52.6 million, 127.6% up from the prior year.
  • Net Income towards Common Stockholders reached -$54.6 million in Q4 2025 per EBS's latest filing, down from $51.2 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $177.9 million in Q4 2021 and bottomed at -$283.1 million in Q2 2024.
  • Average Net Income towards Common Stockholders over 5 years is -$45.1 million, with a median of -$32.0 million recorded in 2021.
  • Peak YoY movement for Net Income towards Common Stockholders: surged 657.6% in 2021, then tumbled 4932.43% in 2023.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at $177.9 million in 2021, then crashed by 142.61% to -$75.8 million in 2022, then soared by 34.7% to -$49.5 million in 2023, then surged by 36.77% to -$31.3 million in 2024, then plummeted by 74.44% to -$54.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income towards Common Stockholders were -$54.6 million in Q4 2025, $51.2 million in Q3 2025, and -$12.0 million in Q2 2025.